Tech Company Financing Transactions
Intellikine Funding Round
Intellikine, operating out of La Jolla, secured $51 million in funding from Biogen Idec, Novartis Venture Fund and U.S. Venture Partners.
Transaction Overview
Company Name
Announced On
7/9/2009
Transaction Type
Venture Equity
Amount
$51,000,000
Round
Undisclosed
Investors
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
10931 N. Torrey Pines Rd. 103
La Jolla, CA 92037
USA
La Jolla, CA 92037
USA
Phone
Website
Email Address
Overview
Intellikine is a leader in the discovery and development of novel, small molecule therapies targeting the PI3K/Akt/mTOR pathway.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Troy Wilson
Chief Medical Officer
Greg Berk
Chief Scientific Officer
Christian Rommel
VP - Bus. Development
Paul Resnick
VP - Finance
Heidi Henson
Browse more venture capital transactions:
Prev: 7/9/2009: OpenDNS venture capital transaction
Next: 7/10/2009: Blazent venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We do our best to report on all VC transactions involving tech companies. VC investment data records reported here come from company press releases and news coverage. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs